Uwe Platzbecker. Photo: Stefan Straube, UKL
In patients suffering from myelodysplastic neoplasms (MDS), a group of often mildly progressing bone marrow disorders, the body does not produce enough functional blood cells. Affected individuals suffer from anaemia - a lack of red blood cells and haemoglobin - which can progress to acute leukaemia. Compared to the standard of care, luspatercept can increase haemoglobin levels in MDS patients and help them to avoid blood transfusions. These are the findings of an international clinical trial led by Professor Uwe Platzbecker from Leipzig University and the University of Leipzig Medical Center in collaboration with a large international research team. The results were published in the renowned medical journal -The Lancet-. ...
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
